Arcutis Biotherapeutics ( (ARQT) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arcutis Biotherapeutics’ recent share weakness comes as Wall Street recalibrates expectations rather than abandoning the story. Analysts still see promise in the company’s Zoryve franchise, which they say is showing a strengthening commercial outlook and supports a positive long‑term view.
Mizuho has lowered its price target on Arcutis stock to $35 but kept an Outperform rating. Several other firms have also trimmed their targets into the low‑to‑mid $30 range, signalling that while upside is seen as more modest, sentiment around the business remains generally constructive.
More about Arcutis Biotherapeutics
YTD Price Performance: -7.13%
Average Trading Volume: 1,625,693
Technical Sentiment Signal: Buy
Current Market Cap: $3.35B
For further insights into ARQT stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.